TAK-243

DB15013InvestigationalSmall molecule

TAK-243 is under investigation in clinical trial NCT03816319 (TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia).

Chemical structure of TAK-243
Mechanism
Curator reviewed
Formula / weight
C19H20F3N5O5S2 · 519.51 g/mol (avg)
Code names
AOB87172 · MLN7243 · TAK-243

Resolves to

Compound
UNIIV9GGV0YCDICAS1450833-55-2
Structure
InChIKeyKJDAGXLMHXUAGV-DGWLBADLSA-NSMILESNS(=O)(=O)OC[C@H]1C[C@@H](NC2=CC=NC3=CC(=NN23)C2=CC=CC(SC(F)(F)F)=C2)[C@H](O)[C@@H]1O
Targets
P22314UBA1
Transporters
P08183ABCB1Q9UNQ0ABCG2

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
2TransportersSubstrate / inhibitor direction, not just membership
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
8+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with TAK-243, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In